Bayesian Health vs Cytovale IntelliSep (2026)
Two approaches to the same question, is this patient becoming septic, and they take opposite routes to the answer. Cytovale measures the patient: a cleared in vitro diagnostic that assesses sepsis probability from the mechanical behaviour of the patient's own white blood cells, running on a self contained instrument with a first in class clearance and a published intermediate band that lets the test decline to call it. Bayesian Health reads the record, running machine learning inside the electronic health record continuously, with the deepest prospective evidence base in this index. The practical difference is when and where. In an emergency department, with a patient nobody has data on, a blood test answers and a record based model cannot. On an inpatient ward over three days, continuous monitoring catches what a single draw at admission could not.
- The whole product is a prediction from a routine blood draw rather than from the record, so it works for a patient with no history at that institution, which is exactly the emergency department case.
- The clearance is first in class with a precisely bounded indication, and the intermediate band functions as a published abstention mechanism rather than forcing a binary call.
- It runs on a self contained instrument, so there is no integration project and no dependence on the completeness of the chart.
- Three large prospective multi site cohort studies with a major academic health system, which is the strongest evidence base of any vendor in this index.
- It monitors continuously across the admission rather than at a single moment, so a patient who deteriorates hours after arrival is still covered.
- It runs inside the record system on data already being collected, with no consumable cost per patient and no instrument to site.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Bayesian Health and Cytovale IntelliSep are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Bayesian Health | Cytovale IntelliSep |
|---|---|---|
| Primary category | Inpatient Deterioration & Risk Monitoring | Diagnostics & Genomics |
| Founded | 2018 | Not recorded |
| Headquarters | New York, New York, United States | San Francisco, California |
| Website | bayesianhealth.com | cytovale.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Bayesian Health its top capability grade on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Set against Cytovale IntelliSep, Bayesian Health grades higher on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Its thinnest published disclosure sits on Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards Cytovale IntelliSep its top capability grade on FDA and Regulatory Status. Set against Bayesian Health, Cytovale IntelliSep grades higher on several axes, including Model Supply Chain Disclosure, AI Safety and PHI Stewardship and HIPAA and BAA Posture. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Bayesian Health or Cytovale IntelliSep?
On the axes where the AI Health Index separates them, Bayesian Health grades higher on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency, and Cytovale IntelliSep grades higher on several axes, including Model Supply Chain Disclosure, AI Safety and PHI Stewardship and HIPAA and BAA Posture. Bayesian Health leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Bayesian Health and Cytovale IntelliSep differ most?
The widest separation the AI Health Index records between Bayesian Health and Cytovale IntelliSep is on EHR and Interoperability Depth, where Bayesian Health grades A and Cytovale IntelliSep grades C. That axis sits in the Integration and Deployment group, so it should carry the most weight for a buyer whose binding constraint is how the product lands in the stack already in place.
Where do Bayesian Health and Cytovale IntelliSep grade the same?
The AI Health Index grades Bayesian Health and Cytovale IntelliSep the same on several axes, including Security Certifications and Trust Center, FDA and Regulatory Status and AI Liability and Recourse. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have Bayesian Health and Cytovale IntelliSep not disclosed?
At the last review, at least one of Bayesian Health and Cytovale IntelliSep published thin or absent detail on Model Supply Chain Disclosure. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
These products answer the same clinical question at different moments and with different economics, so a hospital may reasonably deploy both: one is a point in time test with a per test cost, the other is continuous monitoring with an integration cost.
Neither publishes subgroup performance or calibration analysis, and for a test measuring cellular mechanical behaviour the specific exposure is that conditions affecting white cell behaviour, including chronic inflammatory disease and recent chemotherapy, may shift results independently of infection. Bayesian publishes no security attestation, business associate posture or pricing. Cytovale publishes no instrument, cartridge or per test price.